Dr. Reddy's granted FDA nod for first generic targeting Gilead’s Yeztugo
Dr. Reddy's Laboratories received U.S. FDA tentative approval for a generic version of Gilead Sciences' HIV preventative medicine Yeztugo (lenacapavir). The approval allows marketing in 120 low- and middle-income countries, with supplies expected by late 2026. Unitaid estimates the cost at $40 per person-year.
How this was made
The 30-second read
Why it matters
The FDA’s tentative approval for Dr. Reddy’s generic is a regulatory step that can expand future competitive access, but the article explicitly limits marketing to overseas markets and points to a late-2026 supply start.
Market read
A first-to-market generic regulatory milestone for lenacapavir PrEP can re-rate expectations for generic competition, though near-term monetization is constrained.
What to watch
Commercial timing (supplies expected by end of 2026) and licensing/production capacity constraints could delay meaningful revenue contribution despite regulatory progress.
Background
Yeztugo is described as a twice-yearly HIV preventative medicine developed by Gilead, with lenacapavir as the active therapy.
Market effects
Supports the broader narrative of lenacapavir PrEP moving toward off-patent competition, potentially increasing generic supply expectations.
Could shift attention to India-based pharma’s ability to secure U.S. approvals for HIV assets, with near-term revenue skewed to low- and middle-income markets.
May influence global access and pricing expectations for lenacapavir PrEP, affecting demand forecasts for branded and competing generics.
Counterpoint
Tentative approval and overseas-only marketing may limit financial impact versus what investors might assume from a U.S. FDA nod.
Key entities
- companyDr. Reddy's Laboratories
Indian drugmaker receiving the first FDA approval step for a generic targeting Yeztugo/lenacapavir PrEP.
- companyGilead Sciences
Developer of Yeztugo and the licensing counterpart for lenacapavir generics referenced in the article.
- organizationUnitaid
Global health initiative supporting Dr. Reddy’s in securing the approval, cited for expected pricing and supply timing.
